ALLO Allogene Therapeutics, Inc.

NASDAQ
$0.70

Allogene Therapeutics, Inc. (ALLO) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -36.2% since its last earnings release on November 5, 2026.

Allogene Therapeutics Missed Consensus Estimates
Thursday, November 5, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.15)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Allogene Therapeutics, Inc.

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.